Astrazenca Grants Knight Therapeutics License

Astrazeneca signed an exclusive license agreement with Knight Therapeutics (GUD.TO) granting it the rights to sell Movantik, also known as naloxegol, in Canada and Israel.

Under the terms of the deal, Knight will be responsible for all commercial, regulatory and certain supply chain activities for Movantik in Canada and Israel, Knight said in a statement on Thursday.

Movantik, an oral peripherally-acting mu-opioid receptor antagonist approved in Canada for the treatment of opioid-induced constipation in adult patients with non-cancer pain who have had an inadequate response to laxatives, was launched by AstraZeneca in October last year. Movantik sales in Canada were $372,000 for the ten-month period ending October this year, Knight said, citing data from QuintilesIMS.

Leave a Comment